SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Corgentech Inc. will host a webcast teleconference Monday, December 6, 2004 at 8:30 a.m. Eastern Time to review top-line results from PREVENT III, a Phase 3 clinical trial testing edifoligide (E2F Decoy) for the treatment of peripheral artery bypass graft failure.
Interested parties can listen to the live audio webcast, or the subsequent archived recording, by logging on to http://www.corgentech.com/ and going to the Investor Information page. Please connect to Corgentech’s website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by calling 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 2693369.
About Corgentech
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit http://www.corgentech.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include without limitation statements related to our clinical trials, and product candidates. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “slated,” “goal” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties including those relating to results of future clinical trials and the possibility of product approval. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of TF Decoys, progress, timing and results of our clinical trials, intellectual property matters, our ability to timely satisfy the requirements necessary for an NDA submission, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical companies or other therapies, our ability to obtain adequate reimbursement for our lead product candidates and other risks detailed in relevant filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Corgentech Inc.
CONTACT: Jennifer Cook Williams of Corgentech Inc., +1-650-624-9600, orinvestors@corgentech.com; or Daryl Messinger of WeissComm Partners,+1-415-999-2361, or daryl@weisscom.net, for Corgentech Inc.
Web site: http://www.corgentech.com/